glp-1 news october 16 2025 RA Weight Loss Drugs May Carry Untold Ocular Burden How the rise of GLP-1

Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained

In the meantime, hair extensions can provide you with the fullness and and coverage to get you through this phase in your journey

Sleep quality affects GLP-1 sensitivity Poor sleep directly impairs GLP-1 sensitivity and secretion

We also provide innovative treatments like Hydrogen Peroxide Therapy and PlaqueX Therapy, offering alternative approaches to health and wellness